在使用受限平均存活时间的临床试验中对治疗效果进行缩放和解释
Theodore Karrison1, Chen Hu2, James Dignam1
1Public Health Sciences, University of Chicago and NRG/Oncology, Chicago, IL, USA.
Clinical trials (London, England)
|June 14, 2024
概括
新的指标增强了临床试验中受限平均生存时间差异的解释. 这些方法,包括比率和平均差异,有助于评估治疗效应的临床意义.
科学领域:
- 生物统计学 生物统计学
- 临床试验 临床试验
- 生存分析的分析.
背景情况:
- 限制平均存活时间 (RMST) 估计了预期的存活时间,直到指定时间.
- RMST差异是治疗效果的非参数度量,但由于时间缩短,可能难以解释.
- 现有的方法缺乏用于临床意义的直观缩放.
研究的目的:
- 引入和评估基于RMST表达治疗效应的替代指标.
- 提供方法,以提高治疗效果大小在生存研究的解释.
- 用前列腺癌临床试验数据说明这些指标的实用性.
主要方法:
- 限制平均值的计算比率,失去了生命年数的比率,以及生存曲线之间的平均综合差异.
- 利用了两项前列腺癌试验 (NRG/RTOG 0521和NRG/RTOG 0534) 的数据,其中包括总生存期和无进展生存期的终点.
- 证明了这些新效应措施的计算和解释.
主要成果:
- 对于RTOG 0521 (12年视界),RMST差异为0.45年;受限平均数比为1.05;时间损失比为0.81;平均生存率差异为0.038.
- 对于RTOG 0534 (11年视野),RMST差异为1.36年;受限平均数比为1.17;时间损失比为0.56;平均生存率差异为0.12.
- 这些指标提供了缩放的解释,例如,0.45年的差异表明时间损失减少了19%,绝对生存率差异为3.8%.
结论:
- 来自RMST的替代指标为治疗效应大小提供了有价值的见解.
- 这些措施有助于确定观察到的治疗效应的临床意义,而不仅仅是RMST差异.
- 拟议的指标有助于在临床研究中更清晰地传达生存益处.
更多相关视频
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
14.4K
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.7K
相关概念视频
Comparing the Survival Analysis of Two or More Groups
177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
Kaplan-Meier Approach
129
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
129
Actuarial Approach
74
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
74
Survival Curves
131
Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
131
Introduction To Survival Analysis
215
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
215
Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
